Complete genome characterization of SARS-CoV-2 is instrumental in the understanding of the COVID-19 pandemic. The emergence of variants of concern has placed a greater importance in monitoring changes to the SARS-CoV-2 genome through NGS. Gain a deeper understanding of underlying influences affecting vaccine and therapeutic efficacy by monitoring changes in the viral genome over time with our SARS-CoV-2 viral genome assay. We utilize the Ion Ampliseq SARS-CoV-2 Research Panel, a targeted amplicon sequencing chemistry, to provide complete genome coverage and accurate variant calling at low viral loads allowing for flexibility to a range of sample types. This panel consists of 2 primer pools providing redundant coverage minimizing any potential coverage dropout as a result of mutational changes in the viral genome. Using a comprehensive data analysis solution, we are able to deliver a complete SARS-CoV-2 viral genome sequence with accurate variant calling and informed annotation.

NGS Workflow

	Nasopharyngeal Swab NGS assay designed to test wide range of viral loads On-going development expanding acceptable sample types		Viral Load Quantitation Quantitative SARS-CoV-2 Viral Load Assay NGS Library optimized based on viral load
	Viral RNA Isolation High-Throughput Automated Isolation Magnetic bead based viral RNA isolation protocol		Ion Genestudio S5 Sequencing High-Throughput Ion AmpliSeq Technology Complete viral genome coverage with great sensitivity

Thermo Fisher Ion Ampliseq SARS-CoV-2 Research Panel

Reference sequence: MN908947.3

Covers >99% of the SARS-CoV-2 genome, all serotypes included

100% Accuracy and Sensitivity for SNVs and Indels above LoD